SI-BONE reported a 26% increase in worldwide revenue, reaching $20.4 million for Q3 2020, with U.S. revenue up by 27% to $18.9 million. The company's operating loss decreased to $8.7 million, and net loss improved to $9.5 million, or $0.33 per diluted share.
Worldwide revenue increased by 26% to $20.4 million in Q3 2020.
U.S. revenue grew by 27% to $18.9 million in Q3 2020.
Over 50,000 iFuse procedures have been performed by more than 2,200 surgeons worldwide.
Medica, a major commercial payer in Minnesota, now covers iFuse, impacting an estimated 1.1 million covered lives.
SI-BONE expects full year 2020 revenue to be in the range of $73.0-$74.0 million, representing growth of approximately 8%-10% over 2019 revenue.
Visualization of income flow from segment revenue to net income